Skip to content
OpenCapital
Get started

Tango Therapeutics TNGX TNG260Direct Program Expenses-RD — Research And Development Expense

Other segment segments

Personnel-Related Expenses-RD
$12.93M-6.6%
Vopimetostat Direct Program Expenses-RD
$9.33M+70.9%
Facilities And Other Related Expenses-RD
$4.34M-20.6%
TNG456Direct Program Expenses-RD
$2.06M+55.8%
Discovery Direct Program Expenses-RD
$1.87M-60.0%
TNG908Direct Program Expenses-RD
$581K-66.1%
TNG961Direct Program Expenses-RD
$408K-81.6%

Similar metrics at other companies

Scholar Rock logo
SRRKRD Expense Srk439 — Research And Development Expense
$1.76M-58.9%
Nuvalent, Inc. logo
NUVLDiscovery Programs — Direct Expenses Related To Program
$2.8M+31.4%
Scholar Rock logo
SRRKRD Expense Srk181 — Research And Development Expense
$36K-96.8%
Nuvalent, Inc. logo
NUVLNeladalkib — Direct Expenses Related To Program
$26.32M-6.0%
Scholar Rock logo
SRRKEarly Research — Research And Development Expense
$1.21M-16.8%
BridgeBio Pharma logo
BBIOR&D
$126.64M+13.6%

Other financials

Income statement

See full
Revenue--100%
Operating income-$48.8M-14.7%
Net income-$45.5M-14.1%
EPS (diluted)-$0.32+11.1%

Balance sheet

See full
Cash & equivalents$160.0M+162%
Total debt$32.8M-11.3%
Total equity$391.5M+135%
Total assets$435.8M+58.9%

Cash flow

See full
Operating cash flow-$44.4M-6.4%
CapEx-$2.0K-104%
Free cash flow-$44.4M-6.3%

Valuation

See full
Market cap$4.55B+1,915%
Enterprise value$4.43B+2,204%
P/S79.9×+74.4×

Profitability

See full
Operating margin-206.2%-61.0pp
Net margin-188.2%-55.4pp
FCF margin-250.1%-49.4pp

Returns & leverage

See full
Return on equity-38.4%-10.5pp
Debt / equity0.1×-0.1×
Current ratio27.4×+21.1×

Where this comes from

Reported directly by Tango Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tango Therapeutics's tng260direct program expenses-rd — research and development expense.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tango Therapeutics's tng260direct program expenses-rd — research and development expense?
Tango Therapeutics (TNGX) reported tng260direct program expenses-rd — research and development expense of $2.01M in Q1 2026.
How has Tango Therapeutics's tng260direct program expenses-rd — research and development expense changed year-over-year?
Tango Therapeutics's tng260direct program expenses-rd — research and development expense increased by 16.1% year-over-year, from $1.73M to $2.01M.
What is the long-term trend for Tango Therapeutics's tng260direct program expenses-rd — research and development expense?
Over 3 years (2022 to 2025), Tango Therapeutics's tng260direct program expenses-rd — research and development expense has grown at a 8.6% compound annual growth rate (CAGR), from $4.91M to $6.28M.
What does tng260direct program expenses-rd — research and development expense mean?
This metric represents the direct research and development expenditures specifically allocated to the TNG260 clinical or preclinical program. It captures the costs associated with drug discovery, laboratory testing, and clinical trial activities required to advance this specific oncology asset through the development pipeline. Tracking these costs allows investors to assess the capital intensity and resource prioritization of a single therapeutic candidate within the company's broader precision medicine portfolio.